We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

BIO-RAD LABORATORIES

Provides full range of instrumentation, reagent kits, software and quality control systems to clinical laboratories. ... read more Featured Products: More products

Download Mobile App




Specific Gut Bacterium Linked to Irritable Bowel Syndrome

By LabMedica International staff writers
Posted on 08 Dec 2020
The incidence of Irritable Bowel Syndrome (IBS) steeply increases following a gastroenteritis episode, suggesting a possible causative role for microbial perturbation. More...
Gut microbiota composition studies overwhelmingly rely on fecal material.

Fecal and mucus-associated bacteria represent distinctive populations, with the latter more likely to influence the epithelium. In particular, bacterial presence in the inner mucus layer might result in epithelial stress and immune activation. Analyses of fecal microbiota have not demonstrated consistent alterations in IBS.

Biomedical scientists at the University of Gothenburg (Gothenburg, Sweden) and their colleagues prospectively included 62 IBS patients and 31 normal controls that underwent sigmoidoscopy with sampling of biopsies in methanol-Carnoy for future histology/immunohistochemistry and real-time PCR analysis. In a randomly selected subset of participants (the first/explorative cohort, IBS n=22, healthy n=14), mucus was collected from ex vivo sigmoid colon biopsies and analyzed by mass spectrometry (MS).

Mucus samples were prepared for MS according to a modified version of the Filter-Aided Sample Preparation (FASP) protocol. Nano-liquid chromatography-tandem MS was performed on a Q-Exactive instrument (Thermo Fisher Scientific, Bremen, Germany). Histology and immunohistochemistry was performed on tissue sections. Sections were examined using an Eclipse E-1000 epifluorescent microscope (Nikon, Tokyo, Japan). All PCR reactions were carried out in triplicate, using a Bio-Rad CFX96 Real-Time System (Bio-Rad, Hercules., CA, USA).

The investigators reported that metaproteomic analysis of colon mucus samples identified peptides from potentially pathogenic Brachyspira species in a subset of patients with IBS. Using multiple diagnostic methods, mucosal Brachyspira colonization was detected in a total of 19/62 (31%) patients with IBS from two prospective cohorts, versus 0/31 healthy volunteers. The prevalence of Brachyspira colonization in IBS with diarrhea (IBS-D) was 40% in both cohorts. Brachyspira attachment to the colonocyte apical membrane was observed in 20% of patients with IBS and associated with accelerated oro-anal transit, mild mucosal inflammation, mast cell activation and alterations of molecular pathways linked to bacterial uptake and ion–fluid homeostasis. According to species discrimination by real-time PCR, 50% of patients with spirochetosis were colonized by B. pilosicoli; others had either B. aalborgi or the closely related, unconfirmed, species B. hominis.

Magnus Simrén, MD, PhD, a Professor of Gastroenterology, and a co-author of the study, said, “The study suggests that the bacterium may be found in about a third of individuals with IBS. We want to see whether this can be confirmed in a larger study, and we're also going to investigate whether, and how, Brachyspira causes symptoms in IBS. Our findings may open up completely new opportunities for treating and perhaps even curing some IBS patients, especially those who have diarrhea.”

The authors concluded that mucosal Brachyspira colonization was significantly more common in IBS and associated with distinctive clinical, histological and molecular characteristics. The observations suggest a role for Brachyspira in the pathogenesis of IBS, particularly IBS-D. The study was published on November 11, 2020 in the journal GUT.

Related Links:
University of Gothenburg
Thermo Fisher Scientific
Nikon
Bio-Rad



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
New
Staining System
RAL DIFF-QUIK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The new RABTA sets a high standard in laboratory diagnostics (Photo courtesy of Randox)

Pioneering Analyzer with Advanced Biochip Technology Sets New Standard in Lab Diagnostics

A state-of-the-art analyzer combines advanced technology with exceptional efficiency to meet the demanding needs of modern laboratories. Randox Toxicology (Antrim, Ireland) has launched its pioneering... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: How the predictive test works (Photo courtesy of QMUL)

World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment

Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.